HER2 Biomarkers News and reporting on HER2 biomarkers. Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion Premium The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients. Breast Cancer Immunotherapy Response Markers Emerge From Single-Cell Sequencing Study Researchers identified several pre-treatment markers that correlated with T-cell expansion and could be predictive of response to a PD1 inhibitor. Theralink Partners With George Mason, Rutgers Cancer Institute on Breast Cancer Test The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment. Hummingbird Biosciences, Tempus Partner to ID Cancer Patients for Anti-HER3 Treatment Trial The collaboration, through which Hummingbird will have access to Tempus' TIME Trial Network, is focused on advancing the HER3-targeted agent, HMBD-001. Spanish Startup Aims to Develop Novel Genomic Tests to Guide Breast Cancer Treatment Premium Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision. Aug 17, 2020 Thermo Fisher Scientific, Hengrui Therapeutics Ink CDx Deal for Pyrotinib in HER2-Mutated NSCLC Jun 12, 2020 New Data Support Role of Agendia BluePrint Test in Refining Breast Cancer Subtypes Premium Feb 13, 2020 Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel Oct 31, 2019 HER2 Amplification Confers Drug Sensitivity Across Tumor Types in New Study Premium Oct 18, 2019 Cervical Cancer Exomes Point to Potentially Targetable HER, PIK3CA Pathway Changes Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Jun 13, 2019 ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer Premium Apr 3, 2019 Project GENIE Used to Explore Impact of Rare Cancer Mutations on Treatment Response Premium Mar 4, 2019 Colon Cancer Patients Could Benefit From HER2 EGFR Non-Response Findings, Investigators Say Premium Dec 10, 2018 Metastatic ER+ Breast Cancers Acquire HER2 Mutations to Become Treatment Resistant Dec 5, 2018 Genentech Data Shows Breast Cancer Patient Subgroups May Benefit from Its Drugs Premium Sep 5, 2018 Study IDs Triple-Negative Breast Cancer Patients Who Respond to HER2-Targeted Therapy Premium Jul 17, 2018 Strata Oncology to Aid Puma Biotech in Recruiting for Neratinib HER2 Basket Study Feb 1, 2018 Publication Highlights Key Questions as Basket Studies Proliferate Premium Apr 12, 2017 After Korean Clinical Approval for Breast Cancer Prognostic, Gencurix Looks to Asian, US Markets Premium Apr 3, 2017 HER2 Mutant Basket Trial Confirms Drug Response Depends on Mutation, Cancer Type Mar 3, 2017 BioNTech Gathering Data Supporting MammaTyper Over Manual, Digital IHC for Breast Cancer Subtyping Premium Nov 14, 2016 Oncologists, Pathologists Issue HER2 Testing Guidance for Gastroesophageal Cancer Patients Aug 24, 2016 Harvard Breast Cancer Study of HER2 Expression Identifies New Potential Treatment Options Premium Jul 13, 2016 HER2-Positive Breast Cancer Heterogeneity Revealed in Genomic, Transcriptomic Patterns Load More Breaking News Roche Receives EUA for PCR-Based, Point-of-Care SARS-CoV-2 Test Decode Study Identifies Proteomic Predictors of All-Cause Mortality In Brief This Week: Natera, Bruker, Bayer, and More New Products Posted to GenomeWeb: Labcorp, Omniseq, Dovetail Genomics, DNA Script, More People in the News: New Appointments at Sema4, Strata Oncology, Bionano Genomics, More Co-Diagnostics Gets CE Mark for Saliva-Based Molecular SARS-CoV-2 Test The Scan Billions for Antivirals The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports. NFT of the Web Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports. 23andMe on the Nasdaq 23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported. Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.